December 2007- Volume 3, Issue 12

December 2007

In this Issue

Research & Development

SRI vs. HIV

SRI vs. HIV

SRI in new contract with NIAID for preclinical services

Rosetta and NYU expand microRNA collaboration

Rosetta and NYU expand microRNA collaboration

Israel-Rosetta Genomics Ltd. and the New York University School of Medicine have expanded their collaboration to include congenital heart disease.

Gene Logic discovers new use for Pfizer drug

Gene Logic discovers new use for Pfizer drug

Gene Logic Inc. recently announced a collaboration milestone, triggered by the filing of a patent application for a new use of an existing Pfizer drug candidate to treat solid tumors

Putting on a new spin

Putting on a new spin

Amgen spins out Relypsa from newly acquired Ilypsa

Antisense approach to scars

Antisense approach to scars

Isis and Excaliard look to topical antisense drugs to treat scars and other fibrotic conditions

Global News

All that glitters

All that glitters

Nanoengineers mine tiny diamonds for drug delivery

GPC begins restructuring

GPC begins restructuring

Staff reductions of approximately 44 percent are in store for GPC Biotech AG after the recent announcement of a corporate restructuring plan

Allies against Alzheimer’s

Allies against Alzheimer’s

Biogen Idec and Neurimmune to work on antibody-based treatment for AD

Informatics

Free for all (students)

Free for all (students)

Accelrys makes SciTegic Pipeline Pilot Student Edition free to academic researchers

Schizophrenia data deal

Schizophrenia data deal

Genizon Biosciences and NDEI to share samples, technology

Automation & Instrumentation

One molecule at a time

One molecule at a time

Team-up of Agilent and BioNanomatrix focuses on nanoscale whole-genome imaging and analysis

WaferGen’s alpha dog

WaferGen’s alpha dog

Pitt Med School tapped as alpha test site for WaferGen’s real-time PCR system

Xceed launches Strategic Collaborator program

Xceed launches Strategic Collaborator program

Xceed has already committed to several other institutions under its Strategic Collaborator program

Genomics & Proteomics

Band-aid for the brain?

Band-aid for the brain?

Alzheimer’s drugs target symptoms not disease

On your mark, get set...

On your mark, get set...

NextGen appoints new CEO and expands services into protein biomarker monitoring

RXi and Invitrogen: All quiet on the RNAi front

RXi and Invitrogen: All quiet on the RNAi front

RXi Pharmaceutical and Invitrogen announced they have entered into an agreement for RXi to license on an exclusive basis second-generation RNAi technology from Invitrogen for designated target genes in all human therapeutic categories.
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022